Insider TradingJul 22, 2026, 07:02 AM
Tiziana Life Sciences Chairman Buys 42,357 Shares at $0.99
AI Summary
Tiziana Life Sciences' Executive Chairman and Founder, Mr. Gabriele Cerrone, has increased his holdings in the company. Through Panetta Partners Ltd, he purchased an additional 42,357 common shares at $0.99 each, bringing his total ownership to 44,814,587 common shares, representing 34.93% of the issued share capital. The company continues to advance its lead candidate, intranasal foralumab, which has shown promising results in an Expanded Access Program for Non-Active Secondary Progressive Multiple Sclerosis and is currently in a Phase 2a clinical trial.
Key Highlights
- Executive Chairman Gabriele Cerrone purchased 42,357 common shares.
- Shares were acquired at a price of $0.99 per share.
- Total holding of Mr. Cerrone (through Panetta Partners Ltd) is now 44,814,587 common shares.
- This represents 34.93% of Tiziana Life Sciences' issued share capital.
- Intranasal foralumab has shown improvement or stability in 14 na-SPMS patients within 6 months.
- Foralumab is currently in a Phase 2a randomized, double-blind, placebo-controlled trial.
Price Impact
More from TLSA